The UK Prescription Medicine Code of Practice Authority's current Quarterly Review is dominated by cases brought against Astra by Allen & Hanburys and vice versa, and by SmithKline Beecham against Wellcome and vice versa. Here, in brief, are the rulings.
- Astra Pharmaceuticals v Allen & Hanburys: a "Dear Nurse" letter about Diskhalers sent by Allen & Hanburys was found to contain a misleading claim, breaching Clause 7.2 of the Code;
- Allen & Hanburys v Astra: a detail aid for the Turbohaler included studies which were not directly comparable and a table which did not reflect the balance of evidence, breaching Clause 7.2, and a "Dear Doctor" letter which also breached Clause 7.2, the Code Panel ruled. The latter ruling was overturned on appeal, but the Appeal Board decided that the aid's use of an edited quotation did not accurately reflect the author's meaning, breaching Clause 11.2;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze